A new trading day began on Tuesday, with Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) stock price up 0.65% from the previous day of trading, before settling in for the closing price of $460.00. VRTX’s price has ranged from $341.85 to $510.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 27.16% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -97.83%. With a float of $257.43 million, this company’s outstanding shares have now reached $257.70 million.
In an organization with 5400 employees, it is important to assess its efficiency.
Vertex Pharmaceuticals, Inc. (VRTX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Vertex Pharmaceuticals, Inc. is 0.26%, while institutional ownership is 92.70%. The most recent insider transaction that took place on Aug 30 ’24, was worth 1,888,216. In this transaction Executive Chairman of this company sold 3,784 shares at a rate of $499.00, taking the stock ownership to the 9,994 shares. Before that another transaction happened on Aug 30 ’24, when Company’s Director sold 646 for $500.00, making the entire transaction worth $323,000. This insider now owns 4,435 shares in total.
Vertex Pharmaceuticals, Inc. (VRTX) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of 4.08 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -97.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.33% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Trading Performance Indicators
Here are Vertex Pharmaceuticals, Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.03, a number that is poised to hit 4.05 in the next quarter and is forecasted to reach 18.59 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc. (VRTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.29 million. That was better than the volume of 1.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.08%. Additionally, its Average True Range was 9.95.
During the past 100 days, Vertex Pharmaceuticals, Inc.’s (VRTX) raw stochastic average was set at 59.14%, which indicates a significant increase from 20.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 20.27% in the past 14 days, which was higher than the 19.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $481.39, while its 200-day Moving Average is $441.54. However, in the short run, Vertex Pharmaceuticals, Inc.’s stock first resistance to watch stands at $467.36. Second resistance stands at $471.73. The third major resistance level sits at $477.37. If the price goes on to break the first support level at $457.35, it is likely to go to the next support level at $451.70. Assuming the price breaks the second support level, the third support level stands at $447.33.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Key Stats
With a market capitalization of 119.50 billion, the company has a total of 258,053K Shares Outstanding. Currently, annual sales are 9,869 M while annual income is 3,620 M. The company’s previous quarter sales were 2,646 M while its latest quarter income was -3,594 M.
